ATE501725T1 - Parathormon-formulierungen und ihre anwendungen - Google Patents

Parathormon-formulierungen und ihre anwendungen

Info

Publication number
ATE501725T1
ATE501725T1 AT08842081T AT08842081T ATE501725T1 AT E501725 T1 ATE501725 T1 AT E501725T1 AT 08842081 T AT08842081 T AT 08842081T AT 08842081 T AT08842081 T AT 08842081T AT E501725 T1 ATE501725 T1 AT E501725T1
Authority
AT
Austria
Prior art keywords
pth
formulations
parathormone
applications
ionic surfactant
Prior art date
Application number
AT08842081T
Other languages
English (en)
Inventor
Linderoth Dorte Loer
Hansen Lars Lindegaard
Original Assignee
Nycomed Danmark Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark Aps filed Critical Nycomed Danmark Aps
Application granted granted Critical
Publication of ATE501725T1 publication Critical patent/ATE501725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT08842081T 2007-10-26 2008-10-27 Parathormon-formulierungen und ihre anwendungen ATE501725T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99606107P 2007-10-26 2007-10-26
EP07021017A EP2052736A1 (de) 2007-10-26 2007-10-26 Parathyroidhormon-Formulierungen und ihre Verwendungen
PCT/EP2008/009069 WO2009053106A1 (en) 2007-10-26 2008-10-27 Parathyroid hormone formulations and uses thereof

Publications (1)

Publication Number Publication Date
ATE501725T1 true ATE501725T1 (de) 2011-04-15

Family

ID=39146901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08842081T ATE501725T1 (de) 2007-10-26 2008-10-27 Parathormon-formulierungen und ihre anwendungen

Country Status (14)

Country Link
EP (2) EP2052736A1 (de)
AT (1) ATE501725T1 (de)
CY (1) CY1112106T1 (de)
DE (1) DE602008005643D1 (de)
DK (1) DK2219665T3 (de)
ES (1) ES2363272T3 (de)
HR (1) HRP20110444T1 (de)
MX (1) MX2010004388A (de)
PL (1) PL2219665T3 (de)
PT (1) PT2219665E (de)
RU (1) RU2467762C2 (de)
SI (1) SI2219665T1 (de)
WO (1) WO2009053106A1 (de)
ZA (1) ZA201002812B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194570A1 (en) * 2011-04-22 2013-12-30 Radius Health Inc Method of drug delivery for pth, pthrp and related peptides
AU2012255116B2 (en) * 2011-05-18 2017-05-25 Mederis Diabetes, Llc Improved peptide pharmaceuticals
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
CN104704373B (zh) * 2012-08-13 2018-11-16 微型照顾私人有限公司 抗氧化剂在用于血液样品中靶分子检测的方法和装置中的用途
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
KR102676629B1 (ko) 2015-04-29 2024-06-18 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
GB201602880D0 (en) 2016-02-18 2016-04-06 Ge Healthcare Uk Ltd Method and composition for biomolecule stabilization
IL317744A (en) 2016-03-01 2025-02-01 Ascendis Pharma Bone Diseases As PTH drug agonists
PL3518961T3 (pl) 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
FI3518982T3 (fi) 2016-09-29 2025-02-11 Ascendis Pharma Bone Diseases As Säädellysti vapautuvia PTH-yhdisteitä
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CA3107105A1 (en) * 2018-07-30 2020-02-06 Shire-Nps Pharmaceuticals, Inc. Formulations for improved stability of recombinant human parathyroid hormone
US12403182B2 (en) * 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
JP7557544B2 (ja) * 2020-03-30 2024-09-27 スーチュワン ルーチョウ ブーチャン バイオ-ファーマシューティカル カンパニー リミテッド ヒト副甲状腺ホルモン(pth)の製剤及びそれを生成する方法
CN113101275A (zh) * 2021-05-27 2021-07-13 海南通用康力制药有限公司 注射用棓丙酯冻干粉针剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE211655T1 (de) * 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co Iontophoresematrix
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
BRPI0416042A (pt) * 2003-11-13 2007-01-02 Alza Corp composição e aparelho para suprimento transdérmico
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
WO2009053106A1 (en) 2009-04-30
EP2219665A1 (de) 2010-08-25
CY1112106T1 (el) 2015-11-04
RU2010121165A (ru) 2011-12-10
ZA201002812B (en) 2011-12-28
HRP20110444T1 (hr) 2011-08-31
DE602008005643D1 (de) 2011-04-28
SI2219665T1 (sl) 2011-09-30
PT2219665E (pt) 2011-06-29
MX2010004388A (es) 2010-08-10
EP2052736A1 (de) 2009-04-29
RU2467762C2 (ru) 2012-11-27
DK2219665T3 (da) 2011-06-27
ES2363272T3 (es) 2011-07-28
PL2219665T3 (pl) 2011-11-30
HK1146465A1 (en) 2011-06-10
EP2219665B1 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
DE602008005643D1 (de) Parathormon-formulierungen und ihre anwendungen
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CO6311084A2 (es) Combinaciones de compuestos activos que tienen propiedades insecticidas y acaricidas
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
MX2010010508A (es) Composiciones de absorcion de sebo.
ECSP099514A (es) Antagonistas de activina-actrii y usos para aumentar los niveles de glóbulos rojos
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
DK1819227T3 (da) Farmaceutisk formulering af decitabin
CO6280573A2 (es) Concentrados en suspension basados en aceite
BR112012009487A2 (pt) formulações de espessante estáveis
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
CY1108196T1 (el) Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα
EP2153831A4 (de) Antiermüdungsmittel und orale zusammensetzung, beide mit andrographolid als wirkstoff
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
NO20091517L (no) Emulsjon
EP2692723A8 (de) Aryloxydihalopropenyl-ether-verbindung und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2219665

Country of ref document: EP